OnCo

TNFAIP3 (Tumour necrosis factor alpha-induced protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 2 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.

Biology

Ubiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities. Involved in immune and inflammatory responses signalled by cytokines, such as TNF and IL-1 beta, or pathogens via Toll-like receptors (TLRs) through terminating NF-kappa-B activity. Essential component of a ubiquitin-editing protein complex, comprising also RNF11, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signalling pathways. In cooperation with TAX1BP1 promotes disassembly of E2-E3 ubiquitin protein ligase complexes in IL-1R and TNFR-1 pathways; affected are at least E3 ligases TRAF6, TRAF2 and BIRC2, and E2 ubiquitin-conjugating enzymes UBE2N and UBE2D3. In cooperation with TAX1BP1 promotes ubiquitination of UBE2N and proteasomal degradation of UBE2N and UBE2D3. Upon TNF stimulation, deubiquitinates 'Lys-63'-polyubiquitin chains on RIPK1 and catalyses the formation of 'Lys-48'-polyubiquitin chains. Location: Cytoplasm; Nucleus; Lysosome (UniProt). Locus 6q23.3 (HGNC).

Where it is found
  • Non-Hodgkin lymphoma: Open Targets association 0.69 with non-Hodgkin lymphoma (MONDO_0018908)
  • Leukaemia: Open Targets association 0.54 with leukaemia (MONDO_0005059)
  • Skin cancer: Open Targets association 0.53 with skin cancer (MONDO_0002898)
  • Diffuse large B-cell lymphoma: Open Targets association 0.65 with diffuse large B-cell lymphoma (MONDO_0018905); CIViC evidence names this disease
  • Marginal zone lymphoma: Open Targets association 0.52 with marginal zone lymphoma (MONDO_0017604)
Class: tumor suppressor · Gene: TNFAIP3 · Facts checked 2026-09-23 · Target page

External identifiers

Built from HGNC, Ensembl, UniProt and ChEMBL ids

Products by modality and phase

Browse products →

No product in the corpus is aimed at this target yet.

No trial in the corpus names this target or one of its products.

Resistance routes

Unaddressed routes →

The resistance atlas has no route that names this target.

No pathway diagram carries this target as a node.

Companion diagnostics

Assay registry →

No companion diagnostic in the registry measures this target.

Preclinical models

All models →

No model entry for this target yet; check the cancer entries on the models page.

No open questions recorded for this target yet. Suggest one.

Literature

Preprints →
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this target: (TITLE:"TNFAIP3" OR ABSTRACT:"TNFAIP3" OR TITLE:"TNF alpha induced protein 3" OR ABSTRACT:"TNF alpha induced protein 3" OR TITLE:"Tumor necrosis factor alpha-induced protein 3" OR ABSTRACT:"Tumor necrosis factor alpha-induced protein 3" OR TITLE:"A20" OR ABSTRACT:"A20" OR TITLE:"OTUD7C" OR ABSTRACT:"OTUD7C") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TNFAIP3, not a curated reading list.

Export

The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/tnfaip3.json. Licence CC BY-NC 4.0.